SCHEMBL5539893

SCHEMBL5539893

CC(=O)CCCCCc1ccc([O])cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
FAAH O00519 4/20 0.47
ALDH1A1 P00352 1/20 0.47
HSD17B10 Q99714 1/20 0.44
THRA P10827 2/20 0.44
THRB P10828 2/20 0.44
HDAC1 Q13547 3/20 0.43
HDAC2 Q92769 3/20 0.43
ALOX5 P09917 2/20 0.43
ACHE P22303 2/20 0.42
SGMS1 Q86VZ5 2/20 0.42
SGMS2 Q8NHU3 2/20 0.42
CES1 P23141 3/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537456 1.00 MAPT (0.48) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL5541443 0.98 ALDH1A1 (0.48) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL5542827 0.92 HSD17B10 (0.52) MAPTALDH1A1HSD17B10THRATHRB
SCHEMBL9834899 0.85 ACHE (0.60) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL5035009 0.85 NAAA (0.52) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL4383632 0.85 ACHE (0.60) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL11639832 0.85 NAAA (0.52) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL5537458 0.85 ACHE (0.60) MAPTRXFP1FAAHALDH1A1HSD17B10
SCHEMBL5534617 0.84 ALDH1A1 (0.65) MAPTALDH1A1HSD17B10
SCHEMBL11638133 0.83 HDAC3 (0.62) MAPTRXFP1FAAHALDH1A1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885RXFP1 489/4885FAAH 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.